We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store?
Read MoreHide Full Article
Exact Sciences Corporation (EXAS - Free Report) is scheduled to report third-quarter 2019 results on Oct 29, after market close.
The company’s track record has been mixed so far, having delivered a positive surprise thrice in the trailing four quarters and missing the same once, the average positive earnings surprise being 20.97%. In the last reported quarter, Exact Sciences came up with a beat of 46.43%.
Shares of Exact Sciences have soared 52.9% in the year so far against the industry’s decrease of 5%.
Let’s see how things are shaping up for the upcoming quarterly results.
Factors to Consider
Exact Sciences’ top line primarily consists of laboratory service revenues generated from Cologuard, a non-invasive screening test for colorectal cancer. Cologuard test volume increased both year over year and sequentially in the second quarter of 2019, a trend that most likely continued in the third quarter as large number of healthcare providers ordered their first Cologuard test.
In September 2019, the FDA approved a label expansion of Cologuard, which can now be used in eligible average-risk individuals aged 45 years or older, expanding on its previous indication for 50 years or older.
Notably, the label expansion gave Cologuard a wider access to patient population, which increased its market share significantly. The product is likely to have performed well and contributed to significant revenues in the third quarter.
Key Developments
Meanwhile, in July 2019, Exact Sciences announced that it will acquire Genomic Health, Inc. for $2.8 billion to create a leading global cancer diagnostics company. The combined entity will offer two of the strongest and the fastest-growing brands in cancer diagnostics, namely Cologuard and Oncotype DX. The transaction is expected to close by 2019 end.
We expect management to provide an update on the buyout deal during the upcoming earnings call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Exact Sciences this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But this is not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Exact Sciences has an Earnings ESP of -0.82%.
Zacks Rank: Exact Sciences sports a Zacks Rank of 1, which increases the predictive power of ESP. However, its negative ESP leaves surprise prediction inconclusive.
Amgen, Inc. (AMGN - Free Report) has an Earnings ESP of +0.50% and a Zacks Rank of 3. The company is scheduled to release results on Oct 29.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store?
Exact Sciences Corporation (EXAS - Free Report) is scheduled to report third-quarter 2019 results on Oct 29, after market close.
The company’s track record has been mixed so far, having delivered a positive surprise thrice in the trailing four quarters and missing the same once, the average positive earnings surprise being 20.97%. In the last reported quarter, Exact Sciences came up with a beat of 46.43%.
Shares of Exact Sciences have soared 52.9% in the year so far against the industry’s decrease of 5%.
Let’s see how things are shaping up for the upcoming quarterly results.
Factors to Consider
Exact Sciences’ top line primarily consists of laboratory service revenues generated from Cologuard, a non-invasive screening test for colorectal cancer. Cologuard test volume increased both year over year and sequentially in the second quarter of 2019, a trend that most likely continued in the third quarter as large number of healthcare providers ordered their first Cologuard test.
In September 2019, the FDA approved a label expansion of Cologuard, which can now be used in eligible average-risk individuals aged 45 years or older, expanding on its previous indication for 50 years or older.
Notably, the label expansion gave Cologuard a wider access to patient population, which increased its market share significantly. The product is likely to have performed well and contributed to significant revenues in the third quarter.
Key Developments
Meanwhile, in July 2019, Exact Sciences announced that it will acquire Genomic Health, Inc. for $2.8 billion to create a leading global cancer diagnostics company. The combined entity will offer two of the strongest and the fastest-growing brands in cancer diagnostics, namely Cologuard and Oncotype DX. The transaction is expected to close by 2019 end.
We expect management to provide an update on the buyout deal during the upcoming earnings call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Exact Sciences this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But this is not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Exact Sciences has an Earnings ESP of -0.82%.
Zacks Rank: Exact Sciences sports a Zacks Rank of 1, which increases the predictive power of ESP. However, its negative ESP leaves surprise prediction inconclusive.
Exact Sciences Corporation Price and EPS Surprise
Exact Sciences Corporation price-eps-surprise | Exact Sciences Corporation Quote
Stocks That Warrant a Look
Here are a few healthcare stocks worth considering as our model shows that these have the right mix of elements to beat estimates this time around.
Gilead Sciences, Inc. (GILD - Free Report) has an Earnings ESP of +0.91% and a Zacks Rank #3. The company is scheduled to release results on Oct 24. You can see the complete list of today’s Zacks #1 Rank stocks here.
Amgen, Inc. (AMGN - Free Report) has an Earnings ESP of +0.50% and a Zacks Rank of 3. The company is scheduled to release results on Oct 29.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>